MindMed Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Reuters
Oct 30, 2025
MindMed Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced a proposed underwritten public offering of common shares and, to certain investors, pre-funded warrants to purchase common shares. The company will grant underwriters a 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions. Jefferies LLC, Leerink Partners, and Evercore ISI are acting as joint bookrunning managers for the offering. MindMed plans to use net proceeds to fund research and development of its product candidates, as well as for working capital and general corporate purposes. The offering will be made under a shelf registration statement filed with the Securities and Exchange Commission. Final terms will be disclosed in a prospectus supplement to be filed with the SEC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251029885066) on October 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.